Brief: Calithera Biosciences Initiates Keapsake Randomized Phase 2 Trial Of Telaglenastat In Combination With Chemoimmunotherapy

Calithera Biosciences

24/09/2020 12:03

Sept 24 (Reuters) - Calithera Biosciences Inc  CALA.O :
    * CALITHERA BIOSCIENCES INITIATES KEAPSAKE RANDOMIZED PHASE
2
TRIAL OF TELAGLENASTAT IN COMBINATION WITH CHEMOIMMUNOTHERAPY TO
TREAT AGGRESSIVE FORM OF LUNG CANCER
    * CALITHERA BIOSCIENCES INC - ANTICIPATES SHARING INTERIM
DATA
FROM KEAPSAKE TRIAL IN 2021

Source text for Eikon:  ID:nGNX3jB1Kq 
Further company coverage:  CALA.O 

 ((Reuters.Briefs@thomsonreuters.com;))